Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00082888
Status:
COMPLETED
Last Update Posted:
2020-04-13
First Post:
2004-05-14
Brief Title:
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Phase II Evaluation of FTI R115777 in Treatment of Relapsed and Refractory Lymphoma
Status:
COMPLETED
Status Verified Date:
2020-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial studies how well tipifarnib works in treating patients with relapsed or refractory non-Hodgkins lymphoma Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth Tipifarnib may be an effective treatment for non-Hodgkins lymphoma
Detailed Description:
PRIMARY OBJECTIVES
I To assess tumor response to R115777 tipifarnib in patients with relapsed aggressive non-Hodgkins lymphoma Permanently closed to accrual 62806 II To assess tumor response to R115777 in patients with relapsed indolent non-Hodgkins lymphoma Permanently closed to accrual 92607 III To assess tumor response to R115777 in patients with uncommon non-Hodgkins lymphomas
IV To evaluate toxicity associated with this regimen in patients with relapsed non-Hodgkins lymphoma
SECONDARY OBJECTIVES
I To evaluate known and unknown molecular markers that may predict for response to R115777 in lymphoma tissue
OUTLINE
Patients receive tipifarnib orally PO twice daily BID on days 1-21 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
After completion of study treatment patients are followed up every 6 months for 2 years
I To assess tumor response to R115777 tipifarnib in patients with relapsed aggressive non-Hodgkins lymphoma Permanently closed to accrual 62806 II To assess tumor response to R115777 in patients with relapsed indolent non-Hodgkins lymphoma Permanently closed to accrual 92607 III To assess tumor response to R115777 in patients with uncommon non-Hodgkins lymphomas
IV To evaluate toxicity associated with this regimen in patients with relapsed non-Hodgkins lymphoma
SECONDARY OBJECTIVES
I To evaluate known and unknown molecular markers that may predict for response to R115777 in lymphoma tissue
OUTLINE
Patients receive tipifarnib orally PO twice daily BID on days 1-21 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
After completion of study treatment patients are followed up every 6 months for 2 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2012-02849 | REGISTRY | None | None |
| LS038B | None | None | None |
| LS038B | OTHER | None | None |
| 6246 | OTHER | None | None |
| P30CA015083 | NIH | None | None |
| P50CA097274 | NIH | CTEP | httpsreporternihgovquickSearchP50CA097274 |